Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
It was two years ago that 's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA).
Today, however, the company has given up on Aduhelm and is instead focusing on a potentially more promising Alzheimer's drug, Leqembi. It has already obtained accelerated approval and next month it could hit a much more important milestone: full, traditional approval.
Here's why it looks likely to happen and why that's so crucial for Biogen.
Source Fool.com